Thursday’s Highlights at Noon: NovaBay Pharma (NBY), Kandi Technologies (KNDI), AVEO Pharma (AVEO), Agios Pharma (AGIO), OncoSec Medical (ONCS)

By Carrie Williams

So far Thursday, May 16, NASDAQ is up 4.23% and the S&P is up 2.81%. Here are this morning’s most active stocks: NovaBay Pharma (NBYResearch Report), Kandi Technologies (KNDIResearch Report), AVEO Pharma (AVEOResearch Report), Agios Pharma (AGIOResearch Report) and OncoSec Medical (ONCSResearch Report).

NovaBay Pharma is down -12.79% in midday trading to $0.41. Shares opened today at $0.47. The company has a 52-week low of $0.23 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.25, marking a 165.96% potential upside from current levels. In a report issued on March 29, H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on NBY, with a price target of $1, which implies an upside of 113% from current levels.

Kandi Technologies is up 9.87% in midday trading to $5.26. Shares opened today at $4.79. The company has a 52-week low of $3.54 and a 52-week high of $0.00. In the last 30 days, insiders purchased $579.7K worth of KNDI shares. Over the last 3 months, the insider sentiment on Kandi Technologies has been positive based on 14 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

AVEO Pharma is down -9.3% in midday trading to $0.73. Shares opened today at $0.81. The company has a 52-week low of $0.49 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $2.00, marking a 148.45% potential upside from current levels. In a report issued on May 10, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on AVEO, with a price target of $1, which represents a potential upside of 24% from where the stock is currently trading. Separately, on March 15, Robert W. Baird’s Madhu Kumar reiterated a Buy rating on the stock and has a price target of $2. Over the last 3 months, the insider sentiment on AVEO Pharma has been positive based on 115 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Agios Pharma is down -8.03% in midday trading to $49.23. Shares opened today at $53.53. The company has a 52-week low of $41.63 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $87.50, marking a 63.46% potential upside from current levels. In a report released today, RBC analyst Kennen MacKay maintained a Buy rating on AGIO, with a price target of $90, which implies an upside of 68% from current levels. Separately, on May 3, Oppenheimer’s Mark Breidenbach assigned a Hold rating to the stock . Over the last 3 months, the insider sentiment on Agios Pharma has been negative based on 45 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

OncoSec Medical is down -7.48% in midday trading to $0.48. Shares opened today at $0.52. The company has a 52-week low of $0.42 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $5.00, marking a 861.54% potential upside from current levels. In a report issued on April 23, Maxim Group analyst Jason McCarthy maintained a Buy rating on ONCS, with a price target of $5, which implies an upside of 862% from current levels. In the last 30 days, insiders have sold $18.62K worth of ONCS shares.

Trending Stocks Based on Insider Activity >>